Brief: Bayer Says China's National Medical Products Administration Accepted For Review Application For Aflibercept 8 Mg (114.3 Mg/Ml Solution For Injection)
13/08/2026 07:30
BRIEF-Bayer Says China's National Medical Products Administration Accepted For Review Application For Aflibercept 8 Mg (114.3 Mg/Ml Solution For Injection) Aug 13 (Reuters) - BAYER AG BAYGn.DE:
APPLICATION FOR AFLIBERCEPT TO TREAT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION
CHINA’S NATIONAL MEDICAL PRODUCTS ADMINISTRATION HAS ACCEPTED FOR REVIEW THE APPLICATION FOR AFLIBERCEPT 8 MG (114.3 MG/ML SOLUTION FOR INJECTION)
Further company coverage: [BAYGn.DE]
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bayer AG
See all newsBrief: Bayer Says Finerenone Slowed Kidney Decline In CKD
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Deutsche Bank AG FF - Post Stabilisation Notice -Bayer EUR 30NC6 & 30NC9
Brief: Bayer To Present New Finerenone Data Across Chronic Kidney Disease With And Without Diabetes At Asn Kidney Week 2026
Brief: FDA Approves Once-Weekly Generic Hormone Therapy Patch For Women